MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$12,001,300K
Net Income
$3,953,200K
Net Profit Margin
32.94%
EPS
$15.32
Unit: Thousand (K) dollars
Revenue Breakdown
TRIKAFTAKAFTRIO
ALYFTREK
Manufactured Product Other
Collaborativeand Royalty
Revenue Breakdown
US
Europe
Other Countries Outsideofthe Uni...
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Product revenues, net
12,001,300
11,020,100
9,869,200
8,930,700
Cost of sales
1,651,300
1,530,500
1,262,200
1,080,300
Research and development expenses
3,909,500
3,630,300
3,162,900
2,540,300
Acquired in-process research and development expenses
133,000
4,628,400
527,100
115,500
Selling, general and administrative expenses
1,753,100
1,464,300
1,136,600
944,700
Intangible asset impairment charge
379,000
-
-
-
Change in fair value of contingent consideration
2,100
-500
-51,600
-57,500
Total costs and expenses
7,828,000
11,253,000
6,037,200
4,623,300
Income (loss) from operations
4,173,300
-232,900
3,832,000
4,307,400
Interest income
490,900
598,100
614,700
144,600
Interest expense
13,300
30,600
-44,100
-54,800
Other expense, net
-7,700
-86,100
-22,800
-164,800
Income before provision for income taxes
4,643,200
248,500
4,379,800
4,232,400
Provision for income taxes
690,000
784,100
760,200
910,400
Income (loss)
3,953,200
-535,600
3,619,600
3,322,000
Basic EPS
15.46
-2.08
14.05
12.97
Diluted EPS
15.32
-2.08
13.89
12.82
Basic Average Shares
255,700,000
257,900,000
257,700,000
256,100,000
Diluted Average Shares
258,000,000
257,900,000
260,500,000
259,100,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
TRIKAFTAKAFTRIO
$10,312,700K
(0.72%↑ Y/Y)
ALYFTREK
$837,800K
Manufactured Product Other
$820,100K
(4.94%↑ Y/Y)
Product
$11,970,600K
Collaborativeand Royalty
$30,700K
Product revenues, net
$12,001,300K
(8.90%↑ Y/Y)
Income (loss) from
operations
$4,173,300K
(1891.88%↑ Y/Y)
Interest income
$490,900K
(-17.92%↓ Y/Y)
Total costs and
expenses
$7,828,000K
(-30.44%↓ Y/Y)
Income before
provision for income taxes
$4,643,200K
(1768.49%↑ Y/Y)
Interest expense
$13,300K
(-56.54%↓ Y/Y)
Other expense, net
-$7,700K
(91.06%↑ Y/Y)
Research and development
expenses
$3,909,500K
(7.69%↑ Y/Y)
Selling, general and
administrative expenses
$1,753,100K
(19.72%↑ Y/Y)
Cost of sales
$1,651,300K
(7.89%↑ Y/Y)
Intangible asset
impairment charge
$379,000K
Acquired in-process
research and development...
$133,000K
(-97.13%↓ Y/Y)
Change in fair value of
contingent consideration
$2,100K
(520.00%↑ Y/Y)
Income (loss)
$3,953,200K
(838.09%↑ Y/Y)
Provision for income taxes
$690,000K
(-12.00%↓ Y/Y)
Buy us a coffee
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)
logo-vertex-inc-svg copy-svg
VERTEX PHARMACEUTICALS INC MA (VRTX)